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Abstract
Background: It has been suggested that statins substantially reduce the risk of venous thromboembolic events. We sought
to test this hypothesis by performing a meta-analysis of both published and unpublished results from randomised trials of
statins.
Methods and Findings: We searched MEDLINE, EMBASE, and Cochrane CENTRAL up to March 2012 for randomised
controlled trials comparing statin with no statin, or comparing high dose versus standard dose statin, with 100 or more
randomised participants and at least 6 months’ follow-up. Investigators were contacted for unpublished information about
venous thromboembolic events during follow-up. Twenty-two trials of statin versus control (105,759 participants) and seven
trials of an intensive versus a standard dose statin regimen (40,594 participants) were included. In trials of statin versus
control, allocation to statin therapy did not significantly reduce the risk of venous thromboembolic events (465 [0.9%] statin
versus 521 [1.0%] control, odds ratio [OR] = 0.89, 95% CI 0.78–1.01, p= 0.08) with no evidence of heterogeneity between
effects on deep vein thrombosis (266 versus 311, OR 0.85, 95% CI 0.72–1.01) and effects on pulmonary embolism (205 versus
222, OR 0.92, 95% CI 0.76–1.12). Exclusion of the trial result that provided the motivation for our meta-analysis (JUPITER) had
little impact on the findings for venous thromboembolic events (431 [0.9%] versus 461 [1.0%], OR= 0.93 [95% CI 0.82–1.07],
p= 0.32 among the other 21 trials). There was no evidence that higher dose statin therapy reduced the risk of venous
thromboembolic events compared with standard dose statin therapy (198 [1.0%] versus 202 [1.0%], OR= 0.98, 95% CI 0.80–
1.20, p= 0.87). Risk of bias overall was small but a certain degree of effect underestimation due to random error cannot be
ruled out.
Conclusions: The findings from this meta-analysis do not support the previous suggestion of a large protective effect of
statins (or higher dose statins) on venous thromboembolic events. However, a more moderate reduction in risk up to about
one-fifth cannot be ruled out.
Please see later in the article for the Editors’ Summary.
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Introduction
Venous thromboembolic disease (i.e., pulmonary embolism and
deep vein thrombosis) is a common cause of premature death and
morbidity [1–3], yet our knowledge about how to safely prevent it
is limited. During recent years, statins have emerged as one of the
most effective treatments to reduce the burden of arterial
cardiovascular disease worldwide [4]. Because of their remarkably
good safety profile and declining costs, there has been some
interest in their potential use for prevention of other conditions,
such as venous thromboembolic events [5–7]. Venous and arterial
thrombosis often co-occur [8,9] and seem to share some common
risk factors [10]. These epidemiological findings together with
experimental evidence revealing novel mechanisms for the
beneficial effect of statins unrelated to their low density lipoprotein
(LDL) cholesterol lowering effect [11–13] have raised hopes that
statins may also protect against venous thromboembolic events.
Until recently, clinical evidence for the effect of statins on
venous thromboembolism was largely confined to non-randomised
studies (with somewhat contradictory conclusions) [14,15]. In
2009, however, secondary analyses of the JUPITER trial, in which
17,802 apparently healthy men and women were randomly
allocated to receive either rosuvastatin 20 mg daily or matching
placebo, provided direct randomised evidence that statin therapy
might reduce the risk of venous thromboembolic events [5]. In this
trial, allocation to rosuvastatin was associated with a reduction in
the risk of venous thromboembolic events of 43% (95% CI 14%–
63%) during a median 1.9 y follow-up [5], but this was based on
relatively few patients with a venous thromboembolic event (34
versus 60), and so may partly (or even wholly) reflect the play of
chance [16]. This uncertainty was reflected by calls for confirma-
tory evidence from other studies [17,18]. An opportunity to obtain
such evidence is provided by the routinely collected adverse event
reports in existing statin trials. We therefore performed a meta-
analysis of all larger scale trials of a statin versus control, and of a
more intensive versus a less intensive statin regimen [19], which
collected, but did not necessarily publish, information on the
incidence of venous thromboembolic events during follow-up.
Methods
Ethics Statement
Ethics approval was not required for this work.
Search Strategy for Identification of Relevant Studies
PRISMA checklist is provided as Text S1. Study methods have
been summarised in the study protocol (Text S2) and have been
published previously [20]. In brief, we searched MEDLINE
(January 1966 to March 2012), EMBASE (January 1985 to 2012
week 10), and the Cochrane Central Register of Controlled Trials
(The Cochrane Library Issue 2, March 2012) for articles with a
subject term ‘‘hydroxymethylglutaryl-coenzyme A reductase
inhibitor’’ or any of the following terms: ‘‘hydroxymethylglu-
taryl-co A reductase inhibitor,’’ ‘‘statin,’’ ‘‘fluvastatin,’’ ‘‘prava-
statin,’’ ‘‘lovastatin,’’ ‘‘simvastatin,’’ ‘‘atorvastatin,’’ or ‘‘rosuvasta-
tin.’’ The search was limited to randomised controlled trials and
human studies with no language restrictions.
Review Methods and Selection Criteria
Four reviewers, working in pairs, independently screened all
titles and abstracts for randomised controlled trials with either a
parallel or factorial design, with at least one comparison of a statin
versus a control regimen or a more versus less intensive statin
regimen, and with a total of 100 or more randomised participants
followed for at least 6 mo. Reviewing process was piloted for the
first 100 abstracts by all four reviewers (KR, NB, Paul McGale,
and William Majoni) to assess comparability and difficulties. Then,
each abstract was independently reviewed by two researchers and
disagreements resolved by retrieval of the full text article and
discussion with a third person. There were no restrictions placed
on participant characteristics or study outcomes. We also hand-
searched the reference lists of these studies to ensure that other
relevant articles, such as meta-analyses of statin trials or other
types of articles related to statins and venous thromboembolic
events, were not missed. After removing duplicate reports, full text
articles of all remaining reports were examined.
Data Abstraction
For each trial, the following information was recorded: study or
investigator’s name; mean follow-up duration; year of publication
of the primary findings; randomised treatments; mean LDL
cholesterol at 1 y; summary information about the studied
population (number of participants, mean age, number of men,
and prevalence of myocardial infarction or heart failure at
randomisation); and the primary outcome of the study. The
number of patients with at least one reported episode of deep vein
thrombosis or pulmonary embolism was recorded. In trials where
information on such outcomes had not previously been published,
we asked the investigators to abstract the relevant numbers from
their routine records of adverse events. Non-responders were sent
at least one reminder after about 3 wk and were also contacted by
telephone.
Assessment of Risk of Bias
To identify potential sources of bias in the reported events we
followed the Cochrane Collaboration’s risk of bias framework [21]
and considered for each trial the following risk domains: (i)
selection bias (random sequence generation and allocation
concealment); (ii) performance bias (blinding of participants and
study investigators for the outcomes of interest); (iii) detection bias
(blinding of outcome assessors); (iv) attrition bias (incomplete
outcome data); (v) reporting bias (selective outcome reporting).
Risk of bias for each domain was categorised as low, unclear, or
high. This information was used to make judgements about the
overall risk of bias for each trial. We followed the Cochrane
Collaboration’s recommendation to make judgements on the basis
of whether the ranking of the level of bias across domains could
have led to any material bias on the outcomes of interests and,
where applicable, what the direction of the bias would likely be
[21].
Statistical Analysis
Our primary hypothesis was to test whether statin treatment
reduced the risk of venous thromboembolic events. The primary
analyses were, therefore, restricted to trials of statin versus control
(i.e., placebo or usual care). However, since the anti-inflammatory
effect of statins (which could be a potential mechanism for any
venous anti-thrombotic effects) have been suggested to be more
pronounced in high-dose statin therapy [22] and since there is
some non-randomised evidence to suggest a greater reduction in
risk of venous thromboembolic events with higher doses of statins
[19,23], we also performed secondary analyses on the basis of the
trials that had compared a more intensive versus a standard statin
regimen. Odds ratios (ORs) for each trial and summary estimates
of ORs across trials were estimated using Peto’s one-step method
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(see Text S3) [24]. Estimates of heterogeneity between trials were
presented together with I2 statistics and their confidence intervals.
We performed three subgroup analyses: (i) to estimate effects
separately for pulmonary embolism and deep vein thrombosis; (ii)
to estimate effects separately in trials that specifically excluded
patients with a known history of vascular disease compared with
other trials; and (iii) to estimate effects separately according to the
type of statin tested. The summary ORs for subgroups were
compared using a standard chi-squared test. In a sensitivity
analysis, we performed a meta-analysis of the individual trial
results weighted by the absolute LDL cholesterol difference in each
trial at 1 y (Text S3) [4].
Statistical analyses were done using R version 2.11.1 [25]. All
statistical tests were two-sided and all analyses were done on an
intention-to-treat basis.
Results
Out of 4,736 abstracts reviewed, 231 papers describing 112
trials were retrieved for further examination, of which 92 had both
a follow-up duration of 6 mo or longer and had included 100
patients or more (Figure 1). Of these 92 trials, 47 trials comprising
54,643 participants and about 189,800 person-years’ follow-up
were excluded either because no venous thromboembolic events
were recorded (i.e., zero events in both groups after interrogation
of trial database) or because such information was not accessible to
the trial investigators at the time. A further 16 trials comprising
7,846 participants and 18,200 person-years follow-up were
excluded because there was no response to the data request.
Our final database therefore included 29 trials comprising 146,353
participants and about 613,800 person-years follow-up. Of these,
published information about venous thromboembolic events was
available (at the time of our database search) from just two trials
[5,26], but unpublished information was provided by authors for a
further 27 trials. 22 trials compared the effect of statin with control
(105,759 randomised participants and 422,000 person-years
follow-up) [26–46], and seven trials compared a more intensive
with a standard dose statin (40,594 randomised participants and
191,000 person-years follow-up) [47–53], with no overlap between
the two trial groups [39]. The characteristics of the 29 included
trials are shown in Table 1. Risk of bias for individual trials is
summarised in Table 2. Risk of bias for venous thromboembolic
events was deemed low for all included trials.
The primary analyses were restricted to the 22 trials that
compared a statin with a control regimen. In these trials, an
episode of venous thromboembolic event occurred in 986 patients.
Overall, there was no clear evidence that statin therapy reduced
the risk of venous thromboembolic events (465 [0.9%] statin versus
521 [1.0%] control, OR=0.89 [95% CI 0.78–1.01]; p=0.08)
(Figure 2). There was no evidence of heterogeneity in estimated
effect size between the trials (heterogeneity x221=23; p=0.34) but
a moderate degree of statistical inconsistency between the trials
could not be ruled out (I2=0%, 95% CI 0%–43%). Since it was
the result from the JUPITER trial that motivated us to perform
this meta-analysis, it could be argued that that result should be
considered only as ‘‘hypothesis generating,’’ and that including it
in the main analyses may have led to a summary point estimate,
CI, and p-value that are appreciably biased [54,55]. Excluding this
trial, however, had little effect on the overall result (431 [0.9%]
versus 461 [1.0%], OR 0.93; 95% CI 0.82–1.07; p=0.32)
(Figure 2). Virtually identical results were seen when the individual
trial results were weighted by the 1-y LDL cholesterol difference
(in all 22 trials: OR 0.90 per mmol/l LDL cholesterol reduction,
95% CI 0.81–1.00; p=0.05).
In the seven trials that compared a more intensive versus a
standard statin regimen, there was no evidence that higher dose
statin therapy reduced the risk of venous thromboembolic events
compared with standard dose statin therapy (198 [1.0%] versus
202 [1.0%], respectively, OR 0.98; 95% CI 0.80–1.20; p=0.87)
and there was no evidence that the effect varied within these trials
(heterogeneity x6
2=4.5; p=0.61) (Figure 3). However a moderate
to large degree of statistical inconsistency between the trials could
not be ruled out (I2=0%, 95% uncertainty level 0%–61%). The
effect estimates weighted for 1-y LDL cholesterol differences were
similar (weighted OR 0.99, 95% CI 0.66–1.51, per 1 mmol/l LDL
cholesterol reduction).
To assess a possible differential effect of statins (or higher dose
statins) on pulmonary embolism and deep vein thrombosis, we
estimated the effects on each outcome separately. There was no
good evidence that the effect of statin therapy differed by the type of
outcome (x21=0.4, p=0.54 for heterogeneity for the trials of statin
versus control, and x21=3.4, p=0.06 for heterogeneity for the trials
of more intensive versus standard dose statin) (Figure 4). Nor was
there evidence that either statin therapy or higher dose statin
therapy significantly reduced the risk of either type of outcome in
isolation (deep vein thrombosis: 266 versus 311, OR 0.85 [99% CI
0.69–1.06] for trials of statin versus control and 88 versus 106, OR
0.83 [99% CI 0.57–1.21] for trials of more versus less statin;
pulmonary embolism: 205 versus 222, OR 0.92 [99% CI 0.72–
1.19] for trials of statin versus control and 127 versus 107, OR 1.19
[99% CI 0.84–1.68] for trials of more versus less statin) (Figure 4).
In trials that exclusively studied patients with no previous
history of cardiovascular disease [5,27,32,37,43–45], statin therapy
was associated with a significant 38% reduction in the risk of
venous thromboembolism (OR 0.62, 99% CI 0.41–0.94), which
appeared to differ from the non-significant 4% reduction (OR
0.96, 99% CI 0.80–1.15) seen in other trials (p-value for
heterogeneity between two groups of trials = 0.01) (Figure 5).
However, there were no significant differences between the two
groups of trials when the hypothesis-generating JUPITER trial was
excluded from these analyses (p-value for heterogeneity between
two groups of trials after exclusion of JUPITER=0.20).
There was no good evidence that the effect of statin therapy on
venous thromboembolism varied depending on type of statin
studied (x25=10.7, p=0.06) (Figure S1), particularly when the
results from the JUPITER trial were excluded (x25=5.8, p=0.32)
(Figure S2).
Discussion
In this study, we gathered information from over 100,000
participants in 22 randomised trials of statin therapy versus control
and 40,000 participants in seven randomised trials of intensive
versus standard dose statin therapy, which together involve about
14 times as many venous thromboembolic events as previously
reported in the JUPITER study [5]. Overall, the results from this
meta-analysis do not support the suggestion that statins [5] (or
higher doses of statins [19,23]) reduce the risk of venous
thromboembolic events substantially, although a more moderate
reduction in risk up to about one-fifth cannot be ruled out.
Our meta-analysis has several strengths compared to previous
reports. Compared with previous publications that are either based
on non-randomised comparisons or have been based on one single
randomised trial with limited events, our findings are based on
substantially more first events from randomised trials and,
importantly, include previously unpublished as well as published
data. Inclusion of unpublished data helps avoid the well-
documented problems caused by the preferential publication of
Statins for Venous Thromboembolism
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Figure 1. Flow-diagram of search retrieval process.
doi:10.1371/journal.pmed.1001310.g001
Statins for Venous Thromboembolism
PLOS Medicine | www.plosmedicine.org 4 September 2012 | Volume 9 | Issue 9 | e1001310
T
a
b
le
1
.
Su
m
m
ar
y
o
f
tr
ia
ls
ch
ar
ac
te
ri
st
ic
s.
S
tu
d
y
Y
e
a
r
o
f
P
u
b
li
ca
ti
o
n
o
f
M
a
in
R
e
su
lt
s
M
e
a
n
F
o
ll
o
w
-
u
p
(y
)
C
o
u
n
tr
y
/R
e
g
io
n
T
re
a
tm
e
n
t
C
o
m
p
a
ri
so
n
L
D
L
-c
D
if
fe
re
n
ce
(m
m
o
l/
l)
a
P
o
p
u
la
ti
o
n
C
h
a
ra
ct
e
ri
st
ic
s
In
te
rv
e
n
ti
o
n
C
o
n
tr
o
l
R
e
g
im
e
n
M
a
in
In
cl
u
si
o
n
C
ri
te
ri
a
T
o
ta
l
n
P
a
rt
ic
ip
a
n
ts
M
e
a
n
A
g
e
(y
)
M
a
le
(%
)
S
ta
ti
n
v
e
rs
u
s
co
n
tr
o
l
re
g
im
e
n
A
FC
A
P
S/
T
e
xC
A
P
S
[2
7
]
1
9
9
8
5
.3
U
SA
L
2
0
–
4
0
m
g
P
la
ce
b
o
0
.9
4
P
ri
m
ar
y
p
re
ve
n
ti
o
n
6
,6
0
5
5
8
8
5
LI
P
ID
[2
8
]
1
9
9
8
5
.6
A
u
st
ra
lia
,
N
e
w
Z
e
al
an
d
P
4
0
m
g
P
la
ce
b
o
1
.0
3
H
is
to
ry
o
f
M
I
o
r
U
A
9
,0
1
4
6
2
8
3
H
P
S
[2
9
]
2
0
0
2
5
.0
U
K
S
4
0
m
g
P
la
ce
b
o
1
.2
9
V
as
cu
la
r
d
is
e
as
e
o
r
d
ia
b
e
te
s
2
0
,5
3
6
6
4
7
5
P
R
O
SP
ER
[2
6
]
2
0
0
2
3
.2
Sc
o
tl
an
d
,
Ir
e
la
n
d
,
N
e
th
e
rl
an
d
s
P
4
0
m
g
P
la
ce
b
o
1
.0
4
El
d
e
rl
y
w
it
h
va
sc
u
la
r
d
is
e
as
e
o
r
h
ig
h
ri
sk
5
,6
9
9
7
5
4
7
A
SC
O
T
-L
LA
[3
0
]
2
0
0
3
3
.2
N
o
rd
ic
s
an
d
U
K
A
1
0
m
g
P
la
ce
b
o
1
.0
7
H
yp
e
rt
e
n
si
o
n
p
lu
s
o
th
e
r
ri
sk
fa
ct
o
r
1
0
,3
0
5
6
5
8
1
A
LE
R
T
[3
1
]
2
0
0
3
5
.1
M
u
lt
in
at
io
n
al
F
4
0
m
g
P
la
ce
b
o
0
.8
4
R
e
n
al
tr
an
sp
la
n
t
re
ci
p
ie
n
ts
2
,1
0
2
5
0
6
6
C
A
R
D
S
[3
2
]
2
0
0
4
3
.9
U
K
,
Ir
e
la
n
d
A
1
0
m
g
P
la
ce
b
o
1
.1
4
T
yp
e
2
d
ia
b
e
te
s
p
lu
s
o
th
e
r
ri
sk
fa
ct
o
r
2
,8
3
8
6
2
6
8
P
R
EV
EN
D
IT
[3
3
]
2
0
0
4
3
.8
N
e
th
e
rl
an
d
s
P
4
0
m
g
P
la
ce
b
o
1
.0
0
M
ic
ro
al
b
u
m
in
u
ri
c
p
at
ie
n
ts
8
6
4
5
1
6
5
A
LL
IA
N
C
E
[3
4
]
2
0
0
4
4
.3
U
SA
A
1
0
–
8
0
m
g
U
su
al
ca
re
1
.1
6
C
H
D
2
,4
4
2
6
1
8
2
4
D
[3
5
]
2
0
0
5
3
.9
G
e
rm
an
y
A
2
0
m
g
P
la
ce
b
o
0
.8
9
D
ia
b
e
ti
c
h
e
m
o
d
ia
ly
si
s
p
at
ie
n
ts
1
,2
5
5
6
6
5
4
SA
LT
IR
E
[3
6
]
2
0
0
5
2
.2
U
K
A
8
0
m
g
P
la
ce
b
o
1
.7
4
C
al
ci
fi
c
ao
rt
ic
st
e
n
o
si
s
1
5
5
6
8
7
0
M
EG
A
[3
7
]
2
0
0
6
5
.3
Ja
p
an
P
1
0
–
2
0
m
g
N
o
tr
e
at
m
e
n
t
0
.6
7
P
ri
m
ar
y
p
re
ve
n
ti
o
n
7
,8
3
2
5
8
3
0
A
SP
EN
[3
8
]
2
0
0
6
4
.3
M
u
lt
in
at
io
n
al
A
1
0
m
g
P
la
ce
b
o
0
.9
9
T
yp
e
2
d
ia
b
e
te
s
1
,8
6
4
6
1
6
6
SP
A
R
C
L
[3
9
]
2
0
0
6
4
.9
M
u
lt
in
at
io
n
al
A
8
0
m
g
P
la
ce
b
o
1
.4
3
St
ro
ke
o
r
T
IA
,
n
o
C
H
D
4
,7
3
1
6
3
6
0
C
O
R
O
N
A
[4
0
]
2
0
0
7
2
.7
M
u
lt
in
at
io
n
al
R
1
0
m
g
P
la
ce
b
o
1
.6
1
Is
ch
e
m
ic
h
e
ar
t
fa
ilu
re
5
,0
1
1
7
3
7
6
So
la
e
t
al
.
[4
1
]
2
0
0
7
1
.0
U
SA
A
2
0
m
g
P
la
ce
b
o
0
.8
1
N
o
n
is
ch
e
m
ic
h
e
ar
t
fa
ilu
re
1
0
8
5
4
3
3
JU
P
IT
ER
[5
]
2
0
0
8
1
.9
M
u
lt
in
at
io
n
al
R
2
0
m
g
P
la
ce
b
o
1
.0
9
P
ri
m
ar
y
p
re
ve
n
ti
o
n
1
7
,8
0
2
6
6
6
2
G
IS
SI
-H
F
[4
2
]
2
0
0
8
3
.9
It
al
y
R
1
0
m
g
P
la
ce
b
o
0
.9
2
C
H
F
4
,5
7
4
6
8
7
7
M
ET
EO
R
[4
3
]
2
0
0
9
2
.0
M
u
lt
in
at
io
n
al
R
4
0
m
g
P
la
ce
b
o
1
.7
9
P
ri
m
ar
y
p
re
ve
n
ti
o
n
9
8
1
6
0
5
7
LE
A
D
e
[4
4
]
2
0
1
0
1
.5
M
u
lt
in
at
io
n
al
A
8
0
m
g
P
la
ce
b
o
0
.3
0
M
ild
to
m
o
d
e
ra
te
p
ro
b
ab
le
A
lz
h
e
im
e
r
d
is
e
as
e
6
4
0
7
4
4
8
A
ST
R
O
N
O
M
ER
[4
5
]
2
0
1
0
3
.5
C
an
ad
a
R
4
0
m
g
P
la
ce
b
o
1
.7
3
M
ild
to
m
o
d
e
ra
te
ao
rt
ic
st
e
n
o
si
s
2
6
9
5
8
6
1
LO
R
D
[4
6
]
2
0
1
0
2
.5
A
u
st
ra
lia
A
1
0
m
g
P
la
ce
b
o
0
.8
0
C
h
ro
n
ic
ki
d
n
e
y
d
is
e
as
e
1
3
2
6
2
6
5
M
o
re
v
e
rs
u
s
le
ss
in
te
n
si
v
e
st
a
ti
n
th
e
ra
p
y
A
SA
P
[4
7
]
2
0
0
1
2
.0
N
e
th
e
rl
an
d
s
A
8
0
m
g
S
4
0
m
g
0
.6
2
Fa
m
ili
al
h
yp
e
rc
h
o
le
st
e
ro
la
e
m
ia
3
3
0
4
8
4
0
A
-Z
[4
8
]
2
0
0
4
2
.0
M
u
lt
in
at
io
n
al
S
8
0
m
g
S
2
0
m
g
0
.3
0
A
cu
te
co
ro
n
ar
y
sy
n
d
ro
m
e
4
,4
9
7
6
1
7
5
R
EV
ER
SA
L
[4
9
]
2
0
0
4
1
.5
U
SA
A
8
0
m
g
P
4
0
m
g
0
.9
7
.
2
0
%
st
e
n
o
si
s
o
n
ro
u
ti
n
e
co
ro
n
ar
y
an
g
io
g
ra
m
6
5
7
5
6
7
2
P
R
O
V
E
IT
[5
0
]
2
0
0
4
2
.0
M
u
lt
in
at
io
n
al
A
8
0
m
g
P
4
0
m
g
0
.6
5
A
cu
te
co
ro
n
ar
y
sy
n
d
ro
m
e
4
,1
6
2
5
8
7
8
Statins for Venous Thromboembolism
PLOS Medicine | www.plosmedicine.org 5 September 2012 | Volume 9 | Issue 9 | e1001310
positive findings (i.e., publication bias) [16,56]. However, there is a
perception among some that such unpublished data may be of
inferior quality compared with data already in the public domain,
despite the lack of evidence supporting such a view [21,57]. In our
study, reports from all trials had previously been subject to external
peer review and the risk of bias in these trials for the outcomes of
interest was judged to be low in our assessments (Table 2). Most of
the trials had a double-blind design (i.e., trial participants and
investigators were unaware of the treatment allocation) and,
perhaps more importantly, venous thromboembolic events had
been collected routinely as part of the safety and efficacy monitoring
done in each trial (at which point there were no specific hypotheses
related to venous thromboembolic events) [26]. The use of routine
unadjudicated events from these properly designed and conducted
randomised trials is also unlikely to have resulted in any substantial
biases because any under- or over-reporting of events (or, for that
matter, lack of independent confirmation) would be expected to
affect both treatment arms equally [20,58,59]. While systematic
over-reporting of events unaffected by statin therapy would tend to
bias treatment effects towards the null, the magnitude of the bias
would again likely be small because OR estimates are surprisingly
robust to such errors. For example, even if as much as one-quarter
of the reported venous thromboembolic events in our study were
‘‘false’’ events that were unaffected by statin treatment (and hence
equally distributed by treatment group), the estimate of the OR
among the trials of statin versus control would have been expected
to change from 0.89 (shown in Figure 2) to 0.86 as result of removal
of the false events. Confirmation of diagnosis of symptomatic venous
thromboembolism in routine clinical settings already depends on
objective measures such as imaging and biochemistry. It therefore
seems implausible that over-reporting of unrelated outcomes in
these trials of the magnitude needed to result in substantial bias in
OR estimates would have occurred. This is further supported by a
recent study in which treatment effects based on adjudicated versus
unadjudicated vascular events in ten trials involving over 9,000
events were compared, and found to be virtually identical (OR for
reported versus adjudicated outcomes 1.00, 95% CI 0.97–1.02)
[59]. Indeed, if anything, one might expect the reported outcomes
in our study to be more consistent with ‘‘real-world’’ settings in
effectiveness studies and, therefore, more relevant to policy and
practice.
Another concern about inclusion of unpublished data in meta-
analysis is incompleteness in trials gathered, which may itself
become a source of bias [57]. In our study, we sought to obtain
data from all larger trials, including repeated attempts at
contacting study authors. However, we might still have missed
relevant event information from at least 16 further trials where
there was no response from investigators (in another 47 trials,
either no events occurred or events were not available to the
investigators themselves so would therefore not constitute a source
of bias). However, these 16 trials would have contributed only
about an additional 18,000 person-years of exposure (compared to
about 600,000 person-years of exposure in the 29 included trials).
In addition, if an important reduction in venous thromboembo-
lism had been observed in any single trial for which data were not
made available, it seems likely that the result may already have
been published (as most of these trials were completed several
years ago), and hence identified by our literature search. Thus, the
relatively small amount of missing information is unlikely to have
resulted in any material change to our conclusions. This is
illustrated by a recent similar study that assessed the effect of statin
on atrial fibrillation [20]. Additional data on this outcome from a
larger statin trial became available only after the meta-analysis
that combined both published and unpublished data were
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published and this new information was entirely consistent with
the pooled evidence [60].
Nonetheless, it should be recognised that the total number of
first events in our meta-analysis (about 1,000 first reports of venous
thromboembolism) is still relatively modest, as reflected by the
confidence intervals that are consistent with anything from no
effect to a real reduction in risk of about one-fifth. This makes the
results of any subgroup analyses particularly unreliable, and so
they need to be interpreted with due caution [54]. Consequently,
this study cannot reliably investigate the potential differential effect
of statins (or higher dose statins) in certain subgroups of patients
based on important baseline characteristics such as prior history of
venous thromboembolic events and use of anti-platelet or anti-
coagulant therapy, or by the underlying cause of such events (e.g.,
provoked by cancer or other events versus unprovoked events).
Similarly, the suggested heterogeneity in effects on venous
thromboembolism by prior vascular disease (Figure 5) is far from
definitive. While it may be considered biologically plausible for
there to be a proportionally smaller effect among people with pre-
existing vascular disease or other chronic conditions (if the risk of
venous thromboembolic events were less amenable to statin
therapy as the proportion of events that are provoked by causes
Figure 2. Effect of statin therapy on venous thromboembolism.
doi:10.1371/journal.pmed.1001310.g002
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such cancer or immobility increases), the difference seen between
trials that included healthier populations and those that did not
was not statistically significant when the hypothesis-generating
JUPITER trial was excluded (Figure 5). The same observation was
made with regards to type of statins used (Figures S1 and S2).
Thus, to demonstrate such differences (if one were to exist) would
require further evidence from randomised trials.
Might the results be biased in favour of statin therapy owing to
the interdependency of venous and arterial thrombosis? Statins
reduce the risk of arterial vascular events (including hospitalisa-
tions) substantially [4], and more intensive regimens produce
further definite reductions in risk [61]. One might therefore expect
the number of venous thromboembolic events (some of which are
related to arterial cardiovascular events [8,9]) to have been greater
Figure 3. Effect of more intensive versus standard statin therapy on venous thromboembolism.
doi:10.1371/journal.pmed.1001310.g003
Figure 4. Effect of statin therapy on separate components of venous thromboembolism.
doi:10.1371/journal.pmed.1001310.g004
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among patients allocated placebo/less intensive statin regimens.
While this may be plausible, it seems likely that the incidence of
venous thromboembolic events following a cardiovascular event
would be low (for example only six out of the 94 events in
JUPITER occurred following a cardiovascular event) and so
unlikely to have introduced any substantial bias in favour of
statins.
In conclusion, this study provides a more detailed assessment
of the potential effects of statins (or higher dose statins) on venous
thromboembolic events than has previously been possible. We
were unable to confirm the large proportional reduction in risk
suggested by some previous studies. However, a more modest
but perhaps clinically worthwhile reduction in venous thrombo-
embolic events in some or all types of patient cannot be ruled
out.
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Editors’ Summary
Background. Blood normally flows smoothly throughout
the human body, supplying its organs and tissues with
oxygen and nutrients. But, when an injury occurs, proteins
called clotting factors make the blood gel (coagulate) at the
injury site. The resultant blood clot (thrombus) plugs the
wound and prevents blood loss. Occasionally, however, a
thrombus forms inside an uninjured blood vessel and partly
or completely blocks the blood flow. A clot inside one of the
veins (vessels that take blood towards the heart) deep within
the body is called a deep vein thrombosis (DVT). Symptoms
of DVT (which usually occurs in the leg) include pain,
swelling, and redness in the affected limb. DVT is treated
with heparin and warfarin, two anticoagulant drugs that stop
the blood clot growing. If left untreated, part of the clot (an
embolus) can break off and travel to the lungs, where it can
cause a pulmonary embolism (PE), a life-threatening condi-
tion characterized by chest pain, breathlessness, coughing,
and dizziness. Little is known about how to prevent DVTs
and PEs but risk factors for these venous thromboembolic
events include having an inherited blood clotting disorder,
oral contraceptive use, having surgery, and prolonged
inactivity (on long-haul plane flights, for example).
WhyWas This Study Done? In 2009, a secondary (add-on)
analysis of data from a randomized controlled trial (RCT, a
study that randomly assigns individuals to receive different
treatments and compares the outcomes associated with
each treatment) called the JUPITER trial reported that
rosuvastatin—a cholesterol-lowering drug (statin)—halved
the risk of venous thromboembolic events among appar-
ently healthy adults. The JUPITER trial was initiated to test
whether statins reduce the risk of strokes, heart attacks, and
other cardiovascular diseases (conditions that involve the
heart and the blood vessels) among adults with raised levels
of a predictor for these diseases called C-reactive protein;
statins reduce the levels of this protein as well as those of
cholesterol. Because fewer than 100 of the participants in the
JUPITER trial developed a DVT or PE, the reduction in the risk
of a venous thromboembolic event among the participants
who took rosuvastatin could have happened by chance. In
this systematic review and meta-analysis of 29 RCTs of statins
that collected information on many more venous thrombo-
embolic events, the researchers test the hypothesis that
statins substantially reduce the risk of such events. A
systematic review uses predefined criteria to identify all the
research on a given topic; a meta-analysis is a statistical
approach that combines the results of several studies.
What Did the Researchers Do and Find? The researchers
identified 22 RCTs (105,759 participants) that compared the
effects of statins with control (dummy) tablets and seven
(40,594 participants) that compared an intensive statin
regimen with a standard regimen. They then obtained
largely unpublished information about the venous throm-
boembolic events that occurred during these trials (about
1,000 DVTs and PEs) from the original investigators. In the
trials of statin versus control, allocation to statin therapy did
not significantly reduce the risk of venous thromboembolic
events. Thus, although events occurred in 465 participants
who were given statins (0.9% of the participants) and in 521
participants who were given control tablets (1% of the
participants), this difference in outcomes was not statistically
significant—it could have happened by chance. Exclusion of
the JUPITER trial results from the meta-analysis did not alter
this finding. The researchers also found no evidence that
intensive statin therapy reduced the risk of venous throm-
boembolic events compared to standard therapy.
What Do These Findings Mean? The findings of this
meta-analysis do not support the suggestion that statins,
either at the standard dose or at higher doses, reduce the
risk of venous thromboembolic events substantially among
healthy adults. It is possible that the effect of statins has
been underestimated in this meta-analysis because of
missing data or because of some other source of bias.
Furthermore, because the total number of events in this
meta-analysis is still relatively modest, these findings do not
rule out the possibility that statins may reduce the risk of
venous thromboembolic events by up to about one-fifth in
some or all individuals. Additional large RCTs are now
needed to investigate whether statin treatment does in fact
reduce the risk of venous thromboembolic events in adults
and, if it does, whether all statins have a similar effect and
whether statin treatment is beneficial in everyone or only in
specific subgroups of people.
Additional Information. Please access these Web sites via
the online version of this summary at http://dx.doi.org/10.
1371/journal.pmed.1001310.
N This study is further discussed in a PL S Medicine
Perspective by Frits Rosendaal
N The US National Heart Lung and Blood Institute provides
information on deep vein thrombosis (including an
animation about how DVT causes pulmonary embolisms),
and information on pulmonary embolism
N The UK National Health Service Choices website has
information on deep vein thrombosis, including personal
stories, on pulmonary embolism, and on statins; a ‘‘Behind
the Headlines’’ article describes the JUPITER trial and its
implications
N The non-profit organization US National Blood Clot
Alliance provides detailed information about deep vein
thrombosis and pulmonary embolism for patients and
professionals and includes a selection of personal stories
about these conditions
N MedlinePlus has links to further information about deep
vein thrombosis, pulmonary embolism, and statins (in
English and Spanish)
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